JPain 2025 — Altered lipid concentrations associated with anti-SGC IgG and disease severity in FM
One-paragraph summary
A 2025 Journal of Pain paper reporting that FM patients show altered serum lipid concentrations that correlate with both disease severity and anti-satellite-glial-cell IgG antibody levels. Conceptually pairs with the Jakobsson 2026 bile-acid paper as a second metabolomic dimension linked to the autoimmune subtype. Adds a candidate lipid-based biomarker layer for the autoimmune subtype, complementary to the bile-acid layer. Full claim extraction is held until the primary source is fetched and authors verified.
Claims as triples (provisional, pending full-text verification)
- (lipid metabolites) — correlates_with → IgG_fm [evidence: per snippet; confidence: emerging]
- (lipid metabolites) — correlates_with → widespread_pain [confidence: emerging]
Methods note
Cross-sectional case-control suggested by snippet, methodology not captured. Journal of Pain — peer-reviewed.
Limitations
- Citation incomplete; abstract not retrieved. This paper file is a placeholder pending verification of authors, sample size, and analytic approach.
- Lipid metabolomics is a wide net; without seeing the full lipid panel, we can't add specific molecular entities yet.
Open questions raised
- Which lipid classes correlate (free fatty acids? phospholipids? sphingolipids?)?
- Do lipid alterations co-occur with the bile-acid alterations Jakobsson 2026 found, or do they index separate metabolic disturbances?
- Could a combined lipid + BA + anti-SGC IgG panel improve diagnostic AUC for the autoimmune subtype?
Triangulation notes
- Strengthens the autoimmune-FM metabolic-correlate thesis with a second metabolomic dimension beyond bile acids.
- Action item: fetch full text to enable proper triple extraction. Marked in
synthesis/open-questions.mdmigration log.